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the lowest diagnostic detection accuracy (74%), followed by MRI (80%) and EUS 
(94%). With CT as the baseline comparator, the ICERs for MRI ($2,783) and EUS 
($2,200) demonstrated that both were acceptable alternatives. CONCLUSIONS: 
Patients or physicians with low risk-tolerance are advised to avoid the watchful 
waiting approach. EUS, MRI and CT are all cost-effective diagnostic choices. 
Among the four choices, EUS is associated with the lowest risk and highest costs. 
EUS is the best monitoring choice when risk must be minimized irrespective of 
cost. Alternatively, annual MRI and CT scans may serve as a preferred option for 
patients and physicians aiming to balance risk-tolerance with procedure cost.  
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OBJECTIVES: Current guidelines for the management of patients with Barrett’s 
esophagus (BE) with high grade dysplasia recommend radiofrequency ablation 
(RFA) as a treatment, based upon demonstrated clinical and cost-effectiveness. 
For patients with BE with low grade dysplasia (LGD), in contrast, the mainstay of 
management is surveillance endoscopy. The aims of this study were to estimate 
whether RFA is cost-effective for patients with Barrett’s LGD compared to 
surveillance and to determine which factors influence the cost-effectiveness. 
METHODS: A cost-utility analysis was undertaken. A state transition Markov 
model was developed to estimate the costs and benefits of using RFA compared 
to surveillance in LGD. All direct medical costs were estimated from the 
perspective of the Australian health care system with adjustments for the US 
health care system. The model was run for the lifetime of the cohort of patients 
where quality of life differed by disease state. The incremental cost per quality 
adjusted life year (QALY) was estimated and uncertainty was explored using 
sensitivity analyses. RESULTS: Clinical evidence suggests that RFA is superior in 
treating LGD compared to surveillance. Replacing surveillance with RFA would 
yield an additional benefit of 0.129 QALYs. However the cost-effectiveness of RFA 
is highly uncertain. The main drivers of the cost-effectiveness results are the 
effectiveness of RFA, the probability of progression to cancer, and the cost of 
RFA. CONCLUSIONS: The available data suggest that active treatment with RFA 
provides significantly better clinical outcomes than surveillance, but the cost-
effectiveness of RFA in this patient group remains highly uncertain. RFA is not 
cost-effective if the low estimates of cancer risk for LGD from recent population-
based studies are used, but the accuracy of these estimates is unclear. Accurate 
estimates of the risk of developing cancer in patients with no dysplasia or LGD 
are needed to conduct valid and reliable cost-effectiveness analyses.  
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OBJECTIVES: Chronic constipation (CC) is a common chronic functional 
gastrointestinal disorder that may be associated with increased utilization of 
health care resources. The objective of this study was to understand resource 
utilization and associated costs for patients with CC based on treatment 
response. METHODS: A web-based survey was conducted with a sample of 
primary care physicians (PCPs) and gastroenterologists (GEs) across different US 
regions. The survey captured data on referral patterns (to/from GEs), 
test/procedure ordering, and follow-up physician visits for typical patients who 
did and did not achieve satisfactory relief of symptoms to a recent treatment for 
CC (“response”). Survey items included questions regarding the proportion of 
patients who would receive tests/procedures and follow-up physician visits. 
Health care costs were estimated by applying associated unit costs (derived from 
the 2012 Medicare physician payment schedule) to the corresponding utilization. 
All patients were assumed to begin treatment with PCPs. Median and mean costs 
of treatment failure were calculated as the corresponding cost differences 
between physician-deemed non-responders and responders, incorporating both 
PCP work-up costs and the costs of referrals to GEs. RESULTS: Twenty PCPs and 
21 GEs completed the survey. These physicians treated a mean of 58 adults per 
month for CC. Most non-responders were referred to GEs by PCPs (median: 78%; 
mean: 68%). Non-responders were more likely to receive a test/procedure 
compared with responders (median: 90 vs. 0% for both PCPs and GEs; mean: 72 
vs. 5% for PCPs; 72 vs. 24% for GEs). Thyroid function tests and colonoscopy were 
the most common tests/procedures that would be ordered. Median (mean) 
expected cost of follow-up due to non-response was estimated to be $1,132 
($865). CONCLUSIONS: Patients with CC who do not respond satisfactorily to 
treatments are likely to require additional follow-up testing and referrals to 
specialists, potentially leading to increased health care costs.  
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OBJECTIVES: Opioid-induced constipation (OIC) is a common gastrointestinal 
side effect of opioid treatment that can lead to alteration or discontinuation of 
opioid therapy. This multinational cross-sectional survey assessed OIC burden of 
illness. METHODS: Health care providers (HCPs) and a sample of their patients 
prescribed opioids for chronic noncancer pain were surveyed regarding patient 
laxative use, OIC symptoms, treatment patterns, and OIC impact on patient’s 
pain management/daily life. RESULTS: HCPs (n=63) and patients from Canada 
(n=64), France (n=60), Germany (n=60), the UK (n=60), and the United States 
(n=60) participated. Sixty-nine percent of patients were characterized as 
inadequate responders to laxative treatment (used laxatives on ≥4 days in past 
two weeks and had continued constipation symptoms or symptom resolution 
with laxative side effects). Inadequate responders were more likely to have 
started an opioid regimen in the last six months and to have ≤1 bowel movement 
(BM)/wk versus ≥2 compared with responders. The proportion of patients self-
reporting the following common gastrointestinal symptoms were higher than 
what physicians reported as the percent of their patients complaining of these 
symptoms: few normal or spontaneous BMs (88% vs 65%), hard lumpy stools 
(87% vs 71%), BMs different than normal (82% vs 59%), bloating (78% vs 71%), and 
abdominal discomfort/stomach cramps (75% vs 62%). Patients reported taking 
opioids less often (53%) or lowering the dose (57%) as a strategy to alleviate 
constipation, whereas HCPs reported recommending these strategies to 
approximately 10% of their patients with OIC. Approximately 40% of patients 
reported that constipation made it quite a bit harder or extremely harder to live 
with their chronic pain. CONCLUSIONS: Results indicate a disconnect in the 
frequency that OIC symptoms are experienced by patients versus perceived by 
their treating HCPs and also in the frequency of opioid dosing alteration to 
alleviate OIC by patients versus recommended by their HCPs.  
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OBJECTIVES: Constipation is the most common and often most debilitating  
side effect of opioid therapy for chronic pain. It has been reported that some 
patients rank constipation as a more common source of distress than their pain. 
Opioid-induced constipation (OIC) compounds the burden in these patients  
and may lead to opioid alterations in dosing regimen, discontinuation, 
inadequate pain management, and increased cost of care. METHODS: Using 
standard methodology, a targeted literature review was undertaken of studies 
published in the last 10 years (2002–2012) reporting quality of life (QOL) in 
patients with OIC receiving opioid therapy for cancer or noncancer pain. The 
review focused on PubMed (MEDLINE) and Embase; abstracts from recent key 
conferences/meetings for gastroenterology and pain were also reviewed. 
RESULTS: A limited number of publications (one review, four surveys, two small 
qualitative studies) were identified. While only the PAC-QOL has been validated 
in this population, various additional instruments were used to describe OIC 
impact on QOL, such as EQ-5D, the SF-8 questionnaire, a 5-point scale, an 11-
point scale, and qualitative descriptions. The burden of OIC on patient QOL was 
found to be considerable, with OIC patients experiencing worse QOL than 
patients without OIC in all four surveys. Of note, one survey showed that 
increasing severity of constipation correlated with decreasing QOL, while 
another indicated that patients with severe constipation were less satisfied with 
their pain treatment versus patients with mild, moderate, or no constipation. 
Mean satisfaction with pain treatment with no, mild, moderate and severe 
constipation was 6.6, 6.6, 6.2 and 5.2 (10-very satisfied). CONCLUSIONS: Current 
literature on the impact of OIC on QOL is very limited but consistently suggests 
that OIC adversely impacts QOL. More research is needed to fully quantify the 
impact on QOL and standardize research methodology. Alleviation of OIC may 
improve QOL and optimize pain management among these patients.  
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OBJECTIVES: To investigate the factors that potentially influence the UC 
patients’ anxiety and depression after having a colectomy utilizing patient 
survey tools. METHODS: A cross-sectional survey was administered online or via 
paper to patients ≥18 years of age with UC who had a colectomy surgery within 
the last 10 years in Canada, Australia, and the UK. Anxiety and depression was 
measured using the Hospital Anxiety and Depression Scale (HADS); scores > 8 on 
the respective anxiety and depression scales indicate the presence of the 
condition. Other scales used included the Inflammatory Bowel Disease 
Questionnaire (IBDQ), 5-item EuroQol (EQ-5D) questionnaire, Body Image 
Questionnaire (BIQ), Medical Outcomes Study Sexual Functioning Scale (MOS-
SFS), dietary restriction questions, and World Health Organization Health and 
Work Performance Questionnaire-Absenteeism and Presenteeism Questions 
(WHO-HPQ-AP). Logistic regression was used to investigate factors associated 
with anxiety. RESULTS: A total of 424 patients participated from Canada, UK, and 
Australia. Gender was equally distributed with a mean age of 42±13 years. 
Respondents were diagnosed with UC with a mean of 11.8±8.5 years ago and first 
